Los puntos clave no están disponibles para este artículo en este momento.
Radiotherapy plus camrelizumab had manageable toxicity and antitumor efficacy for locally advanced ESCC. Several biomarkers were associated with clinical benefit and deserve further study.
Zhang et al. (Sat,) studied this question.